Welcome to our dedicated page for Enzo Biochem SEC filings (Ticker: ENZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enzo Biochem, Inc. (ENZ / ENZB) SEC filings record provides detailed insight into the company’s evolution as a life sciences tools provider and its eventual transition to private ownership. As an SEC registrant, Enzo filed periodic reports and numerous current reports on Form 8-K that document financial performance, strategic shifts, listing status changes, and corporate transactions.
For investors and researchers, Form 8-K filings are central to understanding key events. In 2024 and 2025, Enzo used 8-Ks to report matters such as NYSE notices of non-compliance, the decision to voluntarily delist from the NYSE and move trading to OTCQX, and the later disclosure that its common stock began trading on OTCQX under the symbol ENZB. A June 24, 2025 Form 8-K describes the Agreement and Plan of Merger with Bethpage Parent, Inc. and Bethpage Merger Sub, Inc., including the proposed cash consideration per share and conditions to closing.
An August 19, 2025 Form 8-K records the shareholder vote at a special meeting where the merger proposal was approved. A subsequent August 20, 2025 Form 8-K reports the completion of the merger, stating that Bethpage Merger Sub, Inc. merged with and into Enzo Biochem, Inc., with Enzo surviving as a wholly owned subsidiary of Bethpage Parent, Inc. That filing explains that each share of common stock was converted into the right to receive cash consideration and that the shares ceased trading on OTCQX and other over-the-counter markets.
On the same date, Enzo filed Form 15 (Form 15-12G), certifying the termination of registration of its common stock under Section 12(g) of the Exchange Act and the suspension of its reporting obligations under Sections 13 and 15(d). The Form 15 identifies the common stock, par value $0.01 per share, as the class of securities covered and notes reliance on Rule 12g-4(a)(1) and Rule 12h-3(b)(1)(i). Together, these filings mark Enzo’s transition from a publicly traded, SEC-reporting issuer to a wholly owned private subsidiary.
On Stock Titan’s filings page, users can review these historical 8-Ks and the Form 15 to trace how Enzo’s life sciences business, listing status, and ownership structure changed over time. AI-powered tools can help summarize the implications of each filing, highlight the sections dealing with merger terms, listing changes, and deregistration, and make it easier to understand the regulatory milestones in Enzo Biochem’s corporate history.
On 23 June 2025, a Schedule 13D/A (Amendment No. 15) was filed for Enzo Biochem, Inc. (symbol ENZ) updating the ownership position of several entities affiliated with the Harbert Discovery investment complex.
Reporting persons: Harbert Discovery Fund, LP; Harbert Discovery Fund GP, LLC; Harbert Discovery Co-Investment Fund I, LP; Harbert Discovery Co-Investment Fund I GP, LLC; Harbert Fund Advisors, Inc.; Harbert Management Corporation; and individuals Jack Bryant and Kenan Lucas. The funds are organized in Delaware, the advisory corporations in Alabama, and the individuals are U.S. citizens.
- Harbert Discovery Fund, LP: 1,763,493 shares (3.36% of outstanding), shared voting and dispositive power.
- Harbert Discovery Co-Investment Fund I, LP: 3,412,420 shares (6.51%), shared voting and dispositive power.
- Aggregate across the group: 5,175,913 shares, representing 9.87% of Enzo Biochem’s common stock, all held with shared voting and dispositive power; no shares are held with sole authority.
The amendment contains no references to legal proceedings, proxy contests, or other corporate actions. It serves solely to refresh beneficial ownership data and confirm that the Harbert entities continue to act as a coordinated group.
Enzo Biochem has announced a definitive agreement to be acquired by Battery Ventures affiliate Bethpage Parent in a $37 million all-cash transaction valued at $0.70 per share. The announcement follows a strategic review initiated by a special board committee in April to explore value-maximizing alternatives.
Key transaction details:
- Transaction expected to close in Q3 2025, subject to shareholder approval and customary conditions
- CEO Kara Cannon communicated the merger details through an employee town hall
- Battery Ventures is described as a global, technology-focused investment firm
The filing includes extensive forward-looking statements and legal disclaimers regarding the merger process, shareholder solicitation details, and SEC filing requirements. Shareholders are urged to review the forthcoming proxy statement containing complete merger information. The company will file additional proxy materials with detailed transaction terms and participant information.
Enzo Biochem, Inc. (ENZ) entered into a definitive Agreement and Plan of Merger on 23 June 2025 with affiliates of Battery Ventures (Bethpage Parent, Inc. and Bethpage Merger Sub, Inc.). The all-cash transaction will convert each outstanding share of Enzo common stock into the right to receive $0.70 per share, excluding (i) shares already held by Parent or Enzo and (ii) any dissenting shares properly perfected under NYBCL §623. At closing, Enzo will survive as a wholly-owned subsidiary of Parent.
Equity instruments: • Vested RSUs held by directors or already vested will be cashed out at $0.70 per underlying share. • Unvested RSUs and all outstanding stock options will be cancelled for no consideration. • All outstanding Company Warrants will be cancelled in exchange for cash amounts set out in individual Warrant Cancellation Agreements executed concurrently with the Merger Agreement.
Board & shareholder alignment: Enzo’s board unanimously approved the Merger Agreement and recommends that shareholders vote FOR the transaction. In support, all officers, directors and the company’s largest shareholder have executed Voting & Support Agreements committing their shares to the deal and restricting transfers, proxies and dissenters’ rights.
Key covenants & restrictions: Enzo is subject to customary no-shop provisions, limits on cash expenditures and a minimum-cash covenant through closing. Representations, warranties and covenants are customary and qualified by SEC disclosure schedules. The company must file a preliminary proxy within 5–10 business days and convene a special meeting to secure majority shareholder approval.
Closing conditions: • Shareholder approval • Accuracy of reps & warranties • Material covenant compliance • Absence of injunctions • No Company Material Adverse Effect • Fewer than 10 % of shares exercising dissenters’ rights • Execution of Warrant Cancellation Agreements by all warrant holders. Target outside date is 23 October 2025.
Termination & fees: Either party may terminate if closing is not achieved by the outside date, among other triggers. Enzo faces a $2.5 million break-up fee plus expense reimbursement up to $1 million under certain scenarios. Parent owes Enzo a $1 million reverse termination fee for specified Parent breaches or failure to close.
The 8-K does not disclose Enzo’s current market price or implied premium, nor any anticipated post-merger strategy. Investors should evaluate the adequacy of the $0.70 cash consideration against their own cost basis and market data once available.